Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of fat in the cytoplasm of hepatocytes in individuals without a history of excessive alcohol consumption, drugs, genetic diseases, or other causes of steatosis (
1,
2). Patients with NAFLD can experience a wide range of clinical manifestations from simple steatosis to liver cirrhosis or hepatocellular carcinoma (
3). In addition to liver disease, NAFLD correlates with other non-communicable disorders. It has been reported that NAFLD is associated with type 2 diabetes, hyperlipidemia, and metabolic syndrome (
3-
5). The disease may also lead to an increase in the risk of developing cardiovascular diseases, chronic renal disorder, or even death (
6). One study conducted in Iran showed a significant correlation of NAFLD with age, body mass index (BMI), aspartate transaminase (AST), alanine aminotransferase (ALT), triglyceride, cholesterol, low-density lipoprotein (LDL) and fasting blood sugar (FBS) (
7). Several studies have indicated that physical activity, socioeconomic status, diabetes, and hypertension are strongly associated with the development of NAFLD (
8).
The NAFLD is a common condition with a global prevalence of 24% (
9). Approximately 27% - 34% of the American population, and about 25% of the European population are afflicted with NAFLD (
10,
11). One study reported that the annual incidence of NAFLD is 6.2% in a community cohort study in adult Sri Lankans who live in urban areas (
12). A pooled estimate analysis showed that the incidence of NAFLD in Asia is 52.34 per 1,000 individuals, although only two studies were included in this analysis (
9). It is estimated that the prevalence of NAFLD would be increasing in the Middle East as a result of increasing related risk factors (
13). In a population-based study performed in the southern part of Iran, the prevalence of NAFLD was estimated at 21.5% (
14). In a cohort study carried out in the northern region of Iran, the prevalence of NAFLD in men and women was estimated to be 40.1% and 44.2%, respectively (
15).
Globally, there are longitudinal studies about the incidence of fatty liver disease and its association with other risk factors, particularly in developing countries. Thus, the estimation of the prevalence and particularly the incidence rate are of importance.